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stitutes, strict pain relief strategy and prognosis were de-
scribed. One of them was severely affected and deceased. 
 Conclusion: This study describes 7 infants with SSSS and 
stresses the important role of skin substitutes as Omiderm  
and Suprathel  as valuable adjuvant treatment modality. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Staphylococcal scalded skin syndrome (SSSS) is a tox-
in-mediated skin disease caused by  Staphylococcus aure-
us and usually seen in neonates and children younger 
than 5 years. It is rarely seen in adults.  S. aureus produc-
es exfoliative toxins which destroy the desmosomes in the 
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 Abstract 
 Background: Staphylococcal scalded skin syndrome (SSSS) 
is a rare toxin-mediated skin disease caused by  Staphylococ-
cus aureus  and seen in infants and children younger than 5 
years.  Objectives: The supportive role of skin substitutes in 
SSSS is stressed as a new and relatively unknown method. 
 Methods: Retrospective observational case-series study, in 
neonates and young infants diagnosed with SSSS.  Results: 
Seven infants with SSSS, treatment with antibiotics, skin sub-
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 Established Facts 
• No adhesive wound dressings for neonates with SSSS.
 Novel Insights 
 • Skin therapy with adhesive skin substitutes in neonates. 
 • Practical guidelines for treatment of neonates with servere SSSS. 
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stratum granulosum of the skin. Clinically, there are su-
perficial blisters without mucosal lesions  [1, 2] .
 SSSS usually presents with sore throat and purulent 
conjunctivitis as the source of infection. In neonates, the 
umbilical cord is often the source of infection. Within
48 h the patient develops fever, malaise and extremely ten-
der erythematous areas on the face, neck, axilla and 
perineum ( fig. 1 a). Flaccid bullae develop within the ery-
thematous areas and the Nikolsky’s sign is positive  [2] . 
The bullae generally affect the bending sides of the ex-
tremities and large areas of the skin may be affected. Bul-
lae enlarge and rupture easily to reveal a moist erythema-
tous base, which gives rise to the scalded appearance. The 
diagnosis of SSSS is clinically and by histopathological ex-
amination of a sample from the roof of a blister ( fig. 1 b).
 Healing occurs without scarring. SSSS usually re-
solves within 7 days but management may be very chal-
lenging and complicated including repeated and daily use 
of sedatives and analgesics for skin treatment  [4–7] . Ad-
hesive wound dressings are not recommended for SSSS, 
but are practical solutions for skin substitution in burns 
 [8, 9] . In this communication, we introduce the treatment 
of 7 infants with SSSS treated with adhesive skin substi-
tutes such as Omiderm  or Suprathel  .
 Method 
 We collected retrospective data of children younger than 1 
year of age admitted to the hospital with SSSS over a period of 4 
years (2004–2008). Data were collected in two medical centers, 
Erasmus MC-Sophia Children’s Hospital and Burn Centre Maas-
stadziekenhuis, Rotterdam, The Netherlands. Age, gender, total 
affected area, culture results, histopathology, time of intensive 
care treatment, amount of analgesics and sedatives, skin treat-
ment, and length of stay were evaluated.
 Results 
 In  table 1 a patient data are summarized. Patient 5 has 
been published before  [10] . Four neonates and 3 infants 
were analyzed. All patients were infected with  S. aureus 
and needed intensive care support. All patients required 
opioid infusion (morphine) and all received paracetamol 
(acetaminophen). Three patients were sedated with mid-
azolam. Six patients were treated with Omiderm and/or 
Suprathel; 5 patients were discharged within 1 week. One 
patient (No. 4) died after severe  Pseudomonas aeruginosa 
sepsis, another patient (No. 1) needed special care for his 
prematurity after recovering from SSSS.
a b
c d
 Fig. 1.   a Scald appearance with blisters and erythema of the trunk.  b Acantholytic cells in the subcorneal re-
gion.  c Abdomen and legs covered with Omiderm  .  d Omiderm  treatment after 4 days. 
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 Discussion 
 SSSS is a potential life-threatening disease especially 
in the first month of life. Differential diagnosis can be 
difficult in the prodromal phase with erythroderma  [12] . 
When blistering is the presenting symptom, SSSS should 
be differentiated from bullous impetigo, epidermolysis 
bullosa, mastocytosis, pemphigus and other congenital 
bullous disorders such as bullous ichthyosis and toxic epi-
dermal necrolysis (TEN). TEN is extremely rare in in-
fancy and caused by necrosis of the epidermis, whereas 
SSSS is caused by acantholysis  [13–15] . In TEN the oral 
mucosa is always involved, whereas it is spared in SSSS. 
A skin biopsy for histological examination is not neces-
sary, the roof of the blisters shows acantholytic cells in 
SSSS. The Tzanck smear is also an easy method to illus-
trate acantholysis  [16] . Determining the exfoliative toxin 
produced by the  S. aureus can be helpful in epidemio-
logical studies during outbreaks on neonatal wards but is 
not necessary for the diagnosis SSSS  [17] . To prevent out-
Table 1a. Summary of patient data
 Patient
1 2 3 4* 5 6 7
Age 3 days 7 months 6 days 18 days 6 days 5 months 11 months
Gender male male male male male female male
Total affected area, % 70 20 70 70 90 30 40
Source of infection umbilical airway umbilical umbilical umbilical nose no source
Histopathology: roof of blister = = = = 4 4 4
Skin therapy: Omiderm = = =† 4 = = =
Highest dose of
morphine, g/kg/h 15 20 20 20 40 10 20
Intensive care, days 3 3 4 4 6 4 3
Seven cases with SSSS. * Deceased. † Also treated with Suprathel. Case 5 published before [11].
Table 1b. Summary of diagnosis and treatment
Diagnosis
Clinical picture Age younger than 5 years
Source of infection: umbilical, conjunctivitis, perioral infection
Erythema with blistering
Progression within hours/day
Histopathology Roof of blister
Culture Skin, umbilical and nose (S. aureus)
Treatment
Environment Sterile undersheets (non-sticky)
Control of humidity and temperature
Isolate patient, control contamination of other patients
Antibiotics Neonates: sepsis therapy with aminoglycosides (Staphylococcus, Pseudomonas)
Flucloxacillin
Control fluid balance Maintenance fluid
Extra fluid based on formula (35 + % damage skin) ! BSA (m2) = ml/h
Covering skin
Analgesia and sedation Acetaminophen
Opiates
Midazolam
Skin care Covering with skin substitutes (Omiderm, Suprathel)
Minimal handling
No application of antibiotic ointments
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breaks of SSSS on neonatal wards it is necessary to isolate 
the patient and during outbreaks it is also necessary to 
treat healthcare workers or parents with mupirocin to 
eradicate nasal carriage of  S. aureus and prevent contam-
ination of other patients  [17] .
 Recently, Blyth et al.  [3] described the diagnosis and 
treatment in 4 older children with SSSS. Skin treatment 
consists of silver sulfadiazine creams and daily dressings 
change under anesthesia on the unit with sedation. Anti-
biotic or antiseptic ointments should also not be applied 
on large areas of the skin because of systemic toxicity by 
absorption of antibiotics, especially in neonates or in-
fants  [5, 7] . Therefore, treatment is required with skin 
substitutes that are applied only. We introduced a new 
skin treatment for SSSS with Omiderm in a case report in 
2006  [11] . After that period, we treated 6 patients with 
SSSS and used Omiderm, in 1 case added with Suprathel 
(case 3). Others reported the use of Omiderm protecting 
the skin of low birth weight infants or in aplasia cutis con-
genita  [18, 19] .
 A case report emphasizes the use of Suprathel in the 
treatment of an infant with TEN  [20] . Recently, Mueller 
et al.  [21] reported an infant with SSSS who was success-
fully treated with Suprathel. Greenwood et al.  [22]  de-
scribed the use of Mepitel  in SSSS patients. The major 
disadvantages of the use of Mepitel are that it is not trans-
parent which renders it impossible to evaluate the skin 
and daily changing of the covering bandages are required.
 Omiderm and Suprathel must be left on the skin be-
cause both skin substitutes are synthetic and there is no 
need to change the dressing ( fig. 1 c). The dressings will 
gradually peel off on their own ( fig. 1 d). Suprathel is also 
biodegradable (see Appendix). In older children we also 
prefer treatment with skin substitutes to improve pain 
relief and fluid control.
 The proposed treatment requires hospitalization, as 
intravenous antibiotics are generally necessary to eradi-
cate the source of staphylococcal infection or coloniza-
tion. However, antibiotics do not influence the progres-
sion of the ‘skin’ manifestations of SSSS. Affected skin 
and blisters were in most cases sterile in classical SSSS by 
definition, but exceptions are reported  [23] . The toxins 
will be neutralized by antibodies and are eliminated in 
the urine  [1, 8] . Generally, sepsis therapy will be chosen 
for neonates, which also covers infections with  P. aerugi-
nosa . Case 4 was not treated with skin substitutes and 
deceased, unfortunately due to  P. aeruginosa  sepsis. This 
case stresses the indication of early use of broad-spec-
trum antibiotics to prevent  P.  aeruginosa sepsis.
 After determining the  S. aureus , a penicillinase-resis-
tant, anti-staphylococcal antibiotic such as flucloxacillin 
is preferred. Depending on the response to treatment, 
oral antibiotics can be substituted within several days. 
The use of pooled human immunoglobulin or fresh-fro-
zen plasma in SSSS has been reported  [3] , but has not been 
investigated in randomized controlled trials  [24] . The use 
of corticosteroids is contraindicated  [4] . In general, pa-
tients with SSSS have extreme pain as did our patients. 
Not only touch but even a draught can cause pain. Neo-
nates may become irritated but may also present with hy-
potonia and lethargic states due to extreme pain. There-
fore, it is important to cover the wounds with an adhesive 
skin substitute.
 We acknowledge the limitation of our study as no con-
trol group was used. Our first experience with Omiderm 
was positive and has shown that the use of Omiderm and 
Suprathel has an analgesic effect. These dressings should 
be applied as soon as possible on the ex foliated skin. In 
addition, pain relief is necessary. Paracetamol in combi-
nation with opiates is required. In our patients we admin-
istered paracetamol and intravenous morphine (1 case 
needed dosages up to 40   g/kg/h) and in 3 cases we also 
added low-dose midazolam (0.1 mg/kg/h). NSAIDs are 
contraindicated. Premature neonates with diminished 
renal function due to hypovolemia, immaturity or use of 
NSAIDs are prone to SSSS due to limited renal elimina-
tion clearance of exfoliative toxins  [1, 8] .
 In most cases, we initially started with a fluid bolus 
when the circulation is threatened by hypovolemia. Many 
referring specialists calculate the fluid needed on the ba-
sis of burns resuscitation formulas (Parkland formula). 
However, patients with SSSS are not similar to burn pa-
tients who have extensive dermal necrosis and capillary 
leakage. The amount of fluid administered using the 
Parkland formula is too much and there is a risk of fluid 
overload and hyponatremia  [3] . In our patients, we used 
another formula that is used in burn care, after the initial 
resuscitation phase  [25] . For children, we advise the 
maintenance requirements plus (35 + TBSA (%))  ! (BSA/
m 2 ) = the amount of fluid in milliliters per hour. There is 
a risk of hyponatremia and isotonic fluids such as saline 
(0.9% NaCl) should be used when substituting for fluid 
losses. In some cases the serum albumin or colloid os-
motic pressure is low and human albumin or plasma ex-
panders are necessary. To control body temperature, neo-
nates are nursed in an incubator with high humidity. 
Children are sometimes nursed in burn units where air, 
humidity and ambient temperature are controlled. En-
teral feeding is encouraged and should be started as soon 
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as possible. Our therapeutic approach is summarized in 
 table 1 b.
 In conclusion, although the external signs of SSSS ap-
pear worse, infants generally recover well and healing is 
usually complete within 5–7 days after starting treat-
ment. Skin substitutes and special care including appro-
priate fluids and analgesics are essential to achieve the 
best results.
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Appendix. Characteristics of Omiderm versus Suprathel
Brand name Omiderm Suprathel 
Generic name water-vapour
permeable poly-
urethane film
synthetic copolymer 
based on dl-lactic 
acid
Application time once once
Non-toxic = =
Flexibility = =
Elasticity 8 =
Sticky 4 =
Pain relief = =
Transparent = after attachment
Expensive 4 =
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